https://www.selleckchem.com/products/gsk805.html
Safety was evaluated by adverse events (AEs) in the pregabalin group. The pooled dataset comprised 700 patients (pregabalin group 302; usual care group 398). All patient-reported outcomes (PRO) scores significantly improved from baseline to week 8 in the pregabalin than in the usual care group (NRS P0.0001; PRSIS P0.0001, and EQ-5D-5L P=0.0006). Overall, all three PRO measures showed greater improvement in the pregabalin than in the usual care group, irrespective of the primary diagnosis. AEs were reported in 36.1% of the pregaba
Like
Comment
Share
